The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 1	2025-01-13		NCT06770296

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Affiliated Hospital of Jiangsu University	7
Affiliated Hospital of Nantong University	71
Shuyang County Traditional Chinese Medicine Hospital	1
The Affiliated Hospital of Xuzhou Medical University	68
The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China	7
The First Affiliated Hospital with Nanjing Medical University	319
The First People's Hospital of Xuzhou	3
The Second People's Hospital of Changshu	2

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Jiangsu Provincial People's Hospital	Nanjing	China	21